The HDAC inhibitors market has witnessed significant growth in recent years, driven by the promising therapeutic potential of these drugs in treating a wide range of diseases, particularly cancer and neurological disorders. HDAC inhibitors are a class of compounds that modulate gene expression by inhibiting the activity of histone deacetylases (HDACs), which in turn plays a crucial role in regulating gene expression. This regulatory mechanism has led to the exploration of HDAC inhibitors as potential therapeutic agents for various diseases, with a focus on oncology and neurology.